Click Here to return To Results

 

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012 See this aricle in Pubmed Article Abstract In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapsed rates and improved neuroradiologic outcomes relative to placebo.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction cop 1 efficacy fumarate MRI MRI,abnormal multiple sclerosis,relapsing multiple sclerosis,treatment of placebo safety treatment of neurologic disorder

Click Here to return To Results